

PARTICULARS TO APPEAR ON THE OUTER PACKAGE {Cardboard carton}

1. NAME OF THE VETERINARY MEDICINAL PRODUCT

SOLENSIA 7 mg/ml solution for injection

2. STATEMENT OF ACTIVE AND OTHER SUBSTANCES

Each vial of 1 ml contains 7 mg frunevetmab

3. PACKAGE SIZE

1 x 1 ml

2 x 1 ml

6 x 1 ml

4. TARGET SPECIES

Cats

5. INDICATION(S)

6. ROUTES OF ADMINISTRATION

Subcutaneous use.

7. WITHDRAWAL PERIODS

8. EXPIRY DATE

Exp. {mm/yyyy}

Once broached use immediately.

9. SPECIAL STORAGE PRECAUTIONS

Store in a refrigerator.

Do not freeze.

Store in the original package.

Protect from light.

10. THE WORDS “READ THE PACKAGE LEAFLET BEFORE USE”

Read the package leaflet before use.

11. THE WORDS “FOR ANIMAL TREATMENT ONLY”

For animal treatment only.

12. THE WORDS “KEEP OUT OF THE SIGHT AND REACH OF CHILDREN”

Keep out of the sight and reach of children.

13. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER

GB only:
Zoetis UK Limited
1st Floor, Birchwood Building
Springfield Drive
Leatherhead
Surrey
KT22 7LP
UK

14. MARKETING AUTHORISATION NUMBERS

Vm 42058/5004

15. BATCH NUMBER

Lot {number}

16. SPECIAL WARNING(S), IF NECESSARY

17. SPECIFIC PRECAUTIONS FOR THE DISPOSAL OF UNUSED PRODUCTS OR WASTE MATERIALS, IF ANY

Disposal: read the package leaflet.

18. CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE IF APPLICABLE

[Distribution category]

POM-V

To be supplied only on veterinary prescription.

MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS
{NATURE/TYPE}

1. NAME OF THE VETERINARY MEDICINAL PRODUCT

SOLENSIA



2. QUALITATIVE AND QUANTITATIVE PARTICULARS OF THE ACTIVE SUBSTANCE(S)

frunevetmab 7 mg/ml

3. BATCH NUMBER

Lot {number}

4. EXPIRY DATE

Exp. {mm/yyyy}

Once broached use immediately.

5. CONTENTS BY WEIGHT, BY VOLUME OR BY NUMBER OF DOSES

6. ROUTE(S) OF ADMINISTRATION

7. WITHDRAWAL PERIOD

8. THE WORDS “FOR ANIMAL TREATMENT ONLY”

PACKAGE LEAFLET:

1. NAME OF THE VETERINARY MEDICINAL PRODUCT

SOLENSIA 7 mg/ml solution for injection for cats

2. COMPOSITION

Each ml of solution contains:

Active substance:

Frunevetmab* 7 mg

* Frunevetmab is a felinised monoclonal antibody (mAb) expressed through recombinant techniques in Chinese hamster ovary (CHO) cells.

The product should appear clear to slightly opalescent solution.

3. TARGET SPECIES

Cats.

4. INDICATIONS FOR USE

For the alleviation of pain associated with osteoarthritis in cats.

5. CONTRAINDICATIONS

Do not use in animals under 12 months and/or under 2.5 kg body weight.

Do not use in cases of hypersensitivity to the active substance or to any of the excipients.

Do not use in animals intended for breeding.

Do not use in pregnant and lactating animals.

6. SPECIAL WARNING(S)

Special warnings:

Continuation of treatment should be based on the individual response of each animal. If a positive response is not observed, consider alternative treatments.

This veterinary medicinal product may induce transient or persistent anti-drug antibodies. The induction of such antibodies may reduce the efficacy of the product although this was not observed during the 84 days of the pivotal clinical trial. No information is available for longer duration treatment.

Special precautions for safe use in the target species:

The safety and efficacy of this product has not been investigated in cats with kidney disease IRIS stages 3 and 4. Use of the product in such cases should be based on a benefit-risk assessment performed by the responsible veterinarian.

Special precautions to be taken by the person administering the veterinary medicinal product to animals:

Hypersensitivity reactions, including anaphylaxis, could potentially occur in the case of accidental self-injection. Repeated accidental self-administration may increase the risk of hypersensitivity reactions.

The importance of Nerve Growth Factor (NGF) in ensuring normal foetal nervous system development is well-established and laboratory studies conducted on non-human primates with human anti-NGF antibodies have shown evidence of reproductive and developmental toxicity. Pregnant women, women trying to conceive, and breastfeeding women should take extreme care to avoid accidental self-injection

In case of accidental self-injection, seek medical advice immediately and show the package leaflet or the label to the physician.

Special precautions for the protection of the environment:

Not applicable.

Pregnancy and lactation:

The safety of the veterinary medicinal product has not been established during pregnancy and lactation or in breeding cats. Laboratory studies with human anti-NGF antibodies in cynomolgus monkeys have shown evidence of teratogenic and foetotoxic effects.

Do not use in pregnant and lactating animals.

Fertility:

Do not use in breeding animals.

Interaction with other medicinal products and other forms of interaction:

None known.

There are no safety data on the concurrent use of non-steroidal anti-inflammatory drugs (NSAIDs) and frunevetmab in the cat. In clinical trials in humans, rapidly progressive osteoarthritis has been reported in patients receiving humanised anti-Nerve Growth Factor (NGF) monoclonal antibody therapy. The incidence of these events increased with high doses and in those human patients that received long-term (more than 90 days) non-steroidal anti-inflammatory drugs (NSAIDs) concomitantly with an anti-NGF monoclonal antibody. Cats have no reported equivalent of human rapidly progressive osteoarthritis. If a vaccine is to be administered at the same time as treatment with frunevetmab, the vaccine should be administered at a different site to that of frunevetmab administration to reduce any potential recruitment of immunogenicity (formation of anti-drug antibodies) to the mAb.

Overdose:

No adverse reactions were observed in laboratory overdose studies when Solensia was administered for 6 consecutive monthly doses at 5 times the maximum recommended dose.

In case of adverse clinical signs after an overdose the cat should be treated symptomatically.

Special restrictions for use and special conditions for use:
Not applicable.

Major incompatibilities:
Do not mix with any other veterinary medicinal product.

7. ADVERSE EVENTS

Cats:

Common (1 to 10 animals / 100 animals treated):	alopecia, dermatitis, pruritus)
Rare (1 to 10 animals / 10,000 animals treated):	injection site reaction (e.g. pain and alopecia) ¹ skin disorders (e.g. skin scab, skin sore)
Very rare (<1 animal / 10,000 animals treated, including isolated reports):	Anaphylaxis (severe allergic reaction) ²

¹ Mild.

² In case of such reactions, appropriate symptomatic treatment should be administered.

Reporting adverse events is important. It allows continuous safety monitoring of a veterinary medicinal product. If you notice any side effects, even those not already listed in this package leaflet, or you think that the medicine has not worked, please contact, in the first instance, your veterinarian. You can also report any adverse events to <the local representative of> the marketing authorisation holder using the contact details at the end of this leaflet, or via your national reporting system.

8. DOSAGE FOR EACH SPECIES, ROUTE(S) AND METHOD OF ADMINISTRATION

Subcutaneous use.

Avoid excessive shaking or foaming of the solution. Administer the entire content (1 ml) of the vial.

Dosage and treatment schedule:

The recommended dose is 1- 2.8 mg/kg bodyweight, once a month.

Dose according to the dosing chart below.

Bodyweight (kg) of cat	SOLENSIA (7 mg/ml) volume to be administered
2.5 - 7.0	1 vial
7.1 - 14.0	2 vials

For cats greater than 7 kg, withdraw the full contents of two vials into the same syringe and administer as a single dose.

9. ADVICE ON CORRECT ADMINISTRATION

Avoid excessive shaking or foaming.

10. WITHDRAWAL PERIOD(S)

Not applicable.

11. SPECIAL STORAGE PRECAUTIONS

Keep out of the sight and reach of children.

Store in a refrigerator (2 °C – 8 °C). Do not freeze.
Store in the original package. Protect from light.

Do not use this veterinary medicinal product after the expiry date which is stated on the label after Exp.

Shelf life after first opening the immediate packaging: use immediately.

12. SPECIAL PRECAUTIONS FOR DISPOSAL

Medicines should not be disposed of via wastewater or household waste.

For EU only: Use take-back schemes for the disposal of any unused veterinary medicinal product or waste materials derived thereof in accordance with local requirements and with any applicable national collection systems.

Ask your veterinary surgeon or pharmacist how to dispose of medicines no longer required. These measures should help to protect the environment.

For GB only: Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal product should be disposed of in accordance with local requirements.

13. CLASSIFICATION OF VETERINARY MEDICINAL PRODUCTS

Veterinary medicinal product subject to prescription.

14. MARKETING AUTHORISATION NUMBERS AND PACK SIZES

Vm 42058/5004

Clear glass Type I vials with bromobutyl rubber stopper and aluminium overseals.
Cardboard box with 1, 2 or 6 vials.

Not all pack sizes may be marketed.

15. PID LINK (Do not print heading)

[The following statement must be included where reference to the European Union Product Database is included on the product information. This statement is relevant to both UK(GB) and UK(NI) products:]

Find more product information by searching for the 'Product Information Database' on www.gov.uk.

16. CONTACT DETAILS

Marketing authorisation holder:

Zoetis UK Limited
1st Floor, Birchwood Building
Springfield Drive
Leatherhead
Surrey
KT22 7LP

Manufacturer responsible for batch release:

Zoetis Belgium
Rue Laid Burniat 1
1348 Louvain-La-Neuve
Belgium

or

Zoetis Belgium SA
Unit 5, Sragh Technology Park
Tullamore
Co. Offaly
Ireland

or

Corden Pharma S.p.A,
Via Dell' Industria 3
20867 Caponago
Monza Brianza
Italy

17. OTHER INFORMATION

Field trials

In clinical trials up to 3 months, treatment of cats with osteoarthritis was demonstrated to have a favourable effect on the reduction of pain assessed by CSOM (Client-Specific Outcome Measures). CSOM is an assessment of an individual cat's response to pain treatment, as assessed by performance of physical activities, sociability and quality of life. The maximum total CSOM score was 15. A total of 182 animals were enrolled in the frunevetmab treatment group and 93 animals included in the placebo group, in the pivotal field trial. Treatment success, defined as a reduction of ≥ 2 in the total CSOM score and no increase in any individual score, was achieved in 66.70%, 75.91% and 76.47% of the

frunevetmab-treated cats and in 52.06%, 64.65% and 68.09% of placebo-treated cats after one, two and three monthly treatments, respectively. Statistically significant difference ($p < 0.05$) compared to placebo-treatment was demonstrated after the first and second treatment, but not after the third treatment.

Gavin Hall
Approved: 26 September 2025